NCT07159763ClinicalTrials.gov
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications
In brief
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza…
Phase 310,000 participants sought211 sites6 countries
Categories
Registered in 1 registry
- ClinicalTrials.govNCT07159763Open this record at ClinicalTrials.govSynced 2 days ago
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-09-08; recorded start 2025-09-25
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 3 other studies in this databaseCounted from the lead sponsor named in the record (Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA))
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 181 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A very large study, international in scope: 10,000 participants (target), run at 211 sites, across 6 countries.
How this score is built
- Enrolment38/40
10,000 participants (target)
- Site count25/25
181 sites
- Country count7/15
5 countries
- Planned duration6/10
Planned over about 20 months
- Sponsor scale2/10
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) has led 4 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza is currently recommended. However, the real-world vaccine effectiveness varied from 10% to 60% in the general population across the years of 2004 to 2024, with effectiveness in most years below 50% (CDC 2025) and decreasing to as low as 5% in immunocompromised individuals (Hughes 2021). The goal of this study is to learn whether MK-1406 (CD388) can help prevent the flu in people who are at higher risk of becoming seriously ill from influenza. Researchers want to find out if MK-1406 dosed at a single study visit can provide protection against influenza compared with placebo. The study will include adolescents and adults who may be more vulnerable to complications from influenza because of their age, health conditions, or weakened immune systems. Researchers will also evaluate the safety of MK-1406 and how well participants tolerate the study medicine.
Conditions
- Influenza
Eligibility
| Sex | All |
|---|---|
| Ages | 12 Years – No maximum |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Phase 3 |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | PREVENTION |
| Masking | QUADRUPLE (4) |
| Enrolment | 10,000 participants sought |
Sponsor and collaborators
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Sponsor
Arms and interventions
- MK-1406EXPERIMENTAL
Participants will receive 450 milligrams (mg) dose of MK-1406 (CD388) by subcutaneous (SC) injection.
- PlaceboPLACEBO_COMPARATOR
Participants will receive placebo by SC injection.
Interventions
- Combination product MK-1406
MK-1406 liquid for injection administered subcutaneously (SC)
- Combination product Placebo
MK-1406 matched liquid for SC injection
Outcome measures
Primary outcome
Number of Participants Experiencing Protocol-defined Influenza-like Illness (ILI) Occurring ≥7 Days after and up to 24 Weeks after Administration of Study Drug
Protocol-defined ILI includes: 1) Influenza infection confirmed by a reverse transcriptase-polymerase chain reaction positive (RT-PCR +) result from nasopharyngeal (NP) swab assayed at a central laboratory AND 2) New onset or worsening of ≥ 2 respiratory symptoms (nasal congestion, sore throat, or cough) OR New onset or worsening of 1 respiratory symptom (nasal congestion, sore throat, or cough) AND new onset of ≥ 1 systemic symptom (headache, feeling feverish or chills, body aches/pains, or fatigue). Number of participants experiencing protocol-defined ILI occurring after administration of MK-1406 (CD388), with influenza infection confirmed by an RT-PCR+ result based on a NP swab assayed at a central laboratory (first occurrence only), as compared to placebo will be assessed.
Time frame Up to approximately 24 weeks post dose
Secondary outcome
Number of participants with ≥1 Adverse Event (AE)
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants with ≥1 AE will be assessed.
Time frame Up to approximately Day 197
Secondary outcome
Number of Participants Who Discontinued from the Study Due to an AE
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued the study because of an AE will be assessed.
Time frame Up to approximately Day 197
Secondary outcome
Number of Participants with Injection Site Reactions (ISRs)
Participants will complete the injection site reaction questionnaire in the eDiary Day 1 through Day 8 following the study intervention administration to assess for reactogenicity, based on the US Food and Drug Administration (FDA) toxicity grading scale used for vaccine trials. Injection site reactions are graded on a scale from 1 to 5 where Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe and Grade 4 is potentially life threatening. The injection-site reactions assessed are pain, tenderness, erythema/redness, and induration/swelling.
Time frame Up to approximately Day 8 post dose
Secondary outcome
Number of Stratum B Participants Experiencing Protocol-defined Influenza-like Illness (ILI) Occurring ≥7 Days after and up to 24 Weeks after Administration of Study Drug
Protocol-defined ILI includes: 1) Influenza infection confirmed by a reverse transcriptase-polymerase chain reaction positive (RT-PCR +) result from nasopharyngeal (NP) swab assayed at a central laboratory AND 2) New onset or worsening of ≥ 2 respiratory symptoms (nasal congestion, sore throat, or cough) OR New onset or worsening of 1 respiratory symptom (nasal congestion, sore throat, or cough) AND new onset of ≥ 1 systemic symptom (headache, feeling feverish or chills, body aches/pains, or fatigue). Number of Stratum B ((immunocompromised participants) experiencing protocol-defined ILI occurring after administration of CD388, with influenza infection confirmed by an RT-PCR+ result based on an NP swab assayed at a central laboratory (first occurrence only), as compared to placebo will be assessed.
Time frame Up to approximately 24 weeks post dose
Secondary outcome
Number of Participants with All-cause Hospitalization within 30 Days after the Onset of Symptomatic Laboratory-Confirmed Influenza
Hospitalizations are defined as an overnight admission in a hospital or similar acute care facility, including emergency rooms due to any cause within 30 days after the onset of symptomatic laboratory-confirmed influenza infection which occurred from ≥ 7 days after and up to 24 weeks after study intervention administration. Number of participants with all-cause hospitalization within 30 days after the onset of symptomatic influenza will be assessed.
Time frame Up to 30 days after onset of symptomatic laboratory-confirmed influenza
Secondary outcome
Number of Participants with All-cause Mortality within 30 Days after the Onset of Symptomatic Laboratory-Confirmed Influenza
Number of participants with mortality due to any cause within 30 days after the onset of symptomatic laboratory-confirmed influenza infection which occurred from ≥ 7 days after and up to 24 weeks after study intervention administration will be determined.
Time frame Up to 30 days after onset of symptomatic laboratory-confirmed influenza
Secondary outcome
Plasma Concentrations Following Administration of MK-1406 (CD388)
Blood samples will be collected at multiple time points to assess the plasma concentrations of MK-1406.
Time frame Day 1 (pre-dose), Day 29, and Day 197 post dose
Secondary outcome
Number of Participants with Treatment Emergent Anti-Drug Antibodies (ADAs)
The number of participants with confirmed anti MK-1406 antibodies post-baseline (i.e. treatment-emergent ADAs) will be determined via evaluation of blood samples collected at multiple time points.
Time frame Day 1 (pre-dose), Day 29, and Day 197 post dose
Secondary outcome
Number of Participants with Treatment Boosted ADAs
The number of participants with an increase in ADA titer over an initial positive baseline titer (i.e., treatment-boosted ADAs) will be determined will be determined via evaluation of blood samples collected at multiple time points.
Time frame Day 1 (pre-dose), Day 29, and Day 197 post dose
Dates
| Start date | September 25, 2025 (actual) |
|---|---|
| Primary completion | July 2, 2027 (estimated) |
| Completion | July 2, 2027 (estimated) |
| First posted | September 8, 2025 (actual) |
| Last updated | November 17, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | November 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
93 sites are recruiting
Argentina
| Facility | City | State or region | Status |
|---|---|---|---|
| CINME - Centro de Investigaciones Metabólicas ( Site 0007) | Buenos Aires | Buenos Aires F.D. | Active, not recruiting |
| Centro de Estudios Infectológicos S.A. ( Site 0002) | CABA | Buenos Aires | Active, not recruiting |
| Equipo Ciencia ( Site 0008) | Ciudad Autonoma de Buenos Aires | Buenos Aires | Active, not recruiting |
| Sanatorio Mayo Privado S.A ( Site 0003) | Córdoba | Córdoba Province | Active, not recruiting |
| Centro Medico de Enfermedades Respiratorias ( Site 0005) | Florida | Buenos Aires | Active, not recruiting |
| Instituto del Buen Aire ( Site 0006) | Santa Fe | Active, not recruiting |
Australia
| Facility | City | State or region | Status |
|---|---|---|---|
| Emeritus Research ( Site 0106) | Botany | New South Wales | Active, not recruiting |
| Core Research Group ( Site 0102) | Brisbane | Queensland | Active, not recruiting |
| Emeritus Research ( Site 0101) | Camberwell | Victoria | Active, not recruiting |
| Australian Clinical Research Network ( Site 0103) | Maroubra | New South Wales | Active, not recruiting |
| The AIM Centre Hunter Diabetes Centre ( Site 0105) | Newcastle | New South Wales | Active, not recruiting |
| Momentum St Leonards ( Site 0107) | St Leonards | New South Wales | Active, not recruiting |
| Momentum Clinical Research Taringa ( Site 0104) | Taringa | Queensland | Active, not recruiting |
Japan
| Facility | City | State or region | Status |
|---|---|---|---|
| Takeuchi Hospital ( Site 0818) | Arakawa City | Tokyo | Recruiting |
| Ishikawa Prefectural Central Hospital ( Site 0814) | Kanazawa | Ishikawa-ken | Recruiting |
| Medical Corporation Chiyukai Shin Komonji Hospital ( Site 0820) | Kitakyushu | Fukuoka | Recruiting |
| National Hospital Organization Tokyo National Hospital ( Site 0802) | Kiyose | Tokyo | Recruiting |
| National Hospital Organization Kumamoto Medical Center ( Site 0801) | Kumamoto | Recruiting | |
| Jobu Hospital for Respiratory Diseases ( Site 0821) | Maebashi | Gunma | Recruiting |
| Maebashi Hirosegawa Clinic ( Site 0804) | Maebashi | Gunma | Recruiting |
| National Hospital Organization Tokyo Medical Center ( Site 0807) | Meguro City | Tokyo | Recruiting |
| Association of Healthcare Corporation Oyama East Clinic ( Site 0823) | Oyama | Tochigi | Recruiting |
| NewHeart Watanabe Institute ( Site 0811) | Suginami | Tokyo | Recruiting |
South Africa
| Facility | City | State or region | Status |
|---|---|---|---|
| Josha Research ( Site 0216) | Bloemfontein | Free State | Active, not recruiting |
| Madibeng Centre for Research ( Site 0201) | Brits | North West | Active, not recruiting |
| TREAD Research ( Site 0206) | Cape Town | Western Cape | Active, not recruiting |
| TASK Applied Science - Headquarter ( Site 0211) | Cape Town | Western Cape | Active, not recruiting |
| Tiervlei Trial Centre ( Site 0204) | Cape Town | Western Cape | Active, not recruiting |
| Centre for the Aids Programme of Research in South Africa. CAPRISA ( Site 0220) | Durban | KwaZulu-Natal | Active, not recruiting |
| Synergy Biomed Research Institute ( Site 0218) | East London | Eastern Cape | Active, not recruiting |
| Ubuntu Clinical Research Center ( Site 0208) | Johannesburg | Gauteng | Active, not recruiting |
| Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0205) | Johannesburg | Gauteng | Active, not recruiting |
| Qhakaza Mbokodo Research Clinic ( Site 0215) | Ladysmith | KwaZulu-Natal | Active, not recruiting |
| Newtown Clinical Research Centre ( Site 0207) | Newtown | Gauteng | Active, not recruiting |
| Paarl Research Centre ( Site 0213) | Paarl | Western Cape | Active, not recruiting |
| Jose Pearson TB Hospital ( Site 0202) | Port Elizabeth | Eastern Cape | Active, not recruiting |
| Global Clinical Trials ( Site 0212) | Pretoria | Gauteng | Active, not recruiting |
| Emmed Research Incorporating ( Site 0209) | Pretoria | Gauteng | Active, not recruiting |
| Jongaie Research ( Site 0214) | Pretoria West | Gauteng | Active, not recruiting |
| Aurum Institute - Rustenburg ( Site 0203) | Rustenburg | North West | Active, not recruiting |
| Welkom Clinical Trial Centre ( Site 0219) | Welkom | Free State | Active, not recruiting |
United Kingdom
| Facility | City | State or region | Status |
|---|---|---|---|
| Aberdeen Royal Infirmary ( Site 0423) | Aberdeen | Aberdeen City | Recruiting |
| Birmingham Heartlands Hospital ( Site 0440) | Birmingham | Recruiting | |
| Queen Elizabeth Hospital ( Site 0411) | Birmingham | Active, not recruiting | |
| Layton Medical Centre ( Site 0405) | Blackpool | Lancashire | Recruiting |
| Bradford Royal Infirmary ( Site 0444) | Bradford | Recruiting | |
| Royal Sussex County Hospital ( Site 0443) | Brighton | Brighton And Hove | Recruiting |
| Southmead Hospital ( Site 0409) | Bristol | Bristol, City of | Active, not recruiting |
| Velocity Clinical Research, Bristol ( Site 0428) | Bristol | Bristol, City of | Recruiting |
| University Hospital of Wales ( Site 0420) | Cardiff | Wales | Active, not recruiting |
161 further sites are listed in the registry record.
Study documents
No documents are linked in this registry record.
Changes over time
- November 13, 2026
Completion date moved later
Primary completion delayed 2 days
2027-06-302027-07-02
- November 6, 2026
Site added
26 sites added (211 total)
185211
- October 27, 2026
Site added
4 sites added (185 total)
181185
- October 15, 2026
Site removed
181 sites removed (181 total)
362181
- October 15, 2026
Status changed
Status changed from Active not recruiting to Recruiting
ACTIVE_NOT_RECRUITINGRECRUITING
- October 15, 2026
Recruitment opened
Recruitment opened
ACTIVE_NOT_RECRUITINGRECRUITING
- September 17, 2026
Completion date moved later
Primary completion delayed 29 days
2027-06-012027-06-30
- September 17, 2026
Site added
181 sites added (362 total)
181362